After over 50 years, the assessment of traumatic brain injuries (TBI) is undergoing a significant transformation aimed at improving diagnosis and treatment. A new framework, developed by a coalition of experts and patients from 14 countries and led by the National Institutes of Health, has been introduced. This framework incorporates biomarkers, neuroimaging scans, and factors such as other medical conditions and the nature of the trauma. The details are published in the May 20 issue of Lancet Neurology.
Kristen Dams-O’Connor, PhD, Director of the Brain Injury Research Center at the Icahn School of Medicine at Mount Sinai and co-first author of the paper, stated that “a complete overhaul of the way we characterize and conceptualize the severity of traumatic brain injury is long overdue.” She explained that traditional terms like ‘mild,’ ‘moderate,’ and ‘severe’ have been inadequate for determining care needs or predicting outcomes. These categories often fail to reflect structural or physiological injuries accurately.
For more than five decades, clinicians have relied on the Glasgow Coma Scale (GCS) to classify TBI patients based on consciousness levels and a few clinical symptoms. This initial diagnosis influenced patient care both in emergency settings and beyond but did not account for crucial modifiers now included in assessments.
The new framework is known as CBI-M and consists of four pillars: clinical assessments, biomarkers, imaging techniques, and modifiers. It was developed by working groups involving over 100 TBI experts, researchers, patients, along with input from the National Institute for Neurological Disorders and Stroke (NINDS).
Dr. Dams-O’Connor highlighted that this initiative results from extensive research collaboration among scientists, clinicians, and federal agencies. She emphasized that federal investments in large-scale studies revealed how GCS could be more informative when its components—eye, verbal, motor responses—are considered separately.
The second pillar involves using blood test biomarkers to provide objective indicators of tissue damage while avoiding unrelated symptoms inclusion. Low biomarker levels can help identify patients who do not require CT scans—reducing unnecessary radiation exposure—and those who can be discharged safely.
In cases with severe injuries where CT or MRI imaging—the third pillar—is necessary; these tools identify blood clots or lesions indicating current/future symptoms.
Currently being phased into trauma centers on trial basis; this proposed framework will undergo refinement before full implementation occurs nationwide.
